https://orcid.org/0000-0001-8353-9092
References
- Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1116–1139. doi:10.1016/j.jacc.2016.03.512.
- Patrono C, Morais J, Baigent C, et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760–1776. doi:10.1016/j.jacc.2017.08.037.
- Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–1232. doi:10.1111/all.12260.
- Plaza-Serón MDC, García-Martín E, Agúndez JA, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update on pharmacogenetics studies. Pharmacogenomics. 2018;19(13):1069–1086. doi:10.2217/pgs-2018-0079.
- Roychowdhury S, Svensson CK. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J. 2005;7(4):E834–E846. doi:10.1208/aapsj070480.
- Garg SK, Sarker CR. Aspirin-induced thrombocytopenia on an immune basis. Am J Med Sci. 1974;267(2):129–132. doi:10.1097/00000441-197402000-00008.
- Mitta A, Curtis BR, Reese JA, et al. Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data. Am J Hematol. 2019;94(3):E76–E78. doi:10.1002/ajh.25379.
- Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):309–314. doi:10.1043/1543-2165-133.2.309.
- Vayne C, Guéry E-A, Rollin J, et al. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2018;19(13):2212. doi:10.2217/pgs-2018-0079
- Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–587. doi:10.1056/NEJMra066469.